3-amino-6-methyl-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione | 1352057-55-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 3-amino-6-methyl-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
• 英文别名: 3-Amino-6-methyl-5H-indeno[1,2-c] isoquinoline-5,11(6H)-dione；3-amino-6-methylindeno[1,2-c]isoquinoline-5,11-dione
• CAS: 1352057-55-6
• 化学式: C₁₇H₁₂N₂O₂
• 分子量: 276.294
• InChiKey: SEUWBQMVQZGVJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-6-methyl-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione 在 四丁基溴化铵 、 氢碘酸 、 palladium diacetate 、 二甲基亚砜 、 三乙胺 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.5h， 生成 (E)-3-(6-methyl-5,11-dioxoindeno[1,2-c]isoquinolin-3-yl)prop-2-enenitrile
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Indenoisoquinoline Rexinoids with Chemopreventive Potential

  摘要：

  Nuclear receptors, such as the retinoid X receptor (RXR), are proteins that regulate a myriad of cellular processes. Molecules that function as RXR agonists are of special interest for the prevention and control of carcinogenesis. The majority of these ligands possess an acidic moiety that is believed to be key for RXR activation. This communication presents the design, synthesis, and biological evaluation of both acidic and nonacidic indenoisoquinolines as new RXR ligands. In addition, a comprehensive structure-activity relationship study is presented that identifies the important features of the indenoisoquinoline rexinoids. The ease of modification of the indenoisoquinoline core and the lack of the necessity of a carboxyl group for activity make them an attractive and unusual family of RXR agonists. This work establishes a structural foundation for the design of new and novel rexinoid cancer chemopreventive agents.

  DOI：

  10.1021/jm400026k

文献信息

• SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (TDP1)- TOPOISOMERASE I (TOP1) INHIBITORS
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：US20130345252A1

  公开（公告）日：2013-12-26

  The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.

  本发明涉及合成和使用某些N-取代吲哚异喹啉化合物，这些化合物抑制酪氨酸-DNA磷酸二酯酶I（Tdp1）或拓扑异构酶I（Top1）或两者的活性，或表现出抗癌活性。还公开了新颖的N-取代吲哚异喹啉化合物和包含这些新颖的N-取代吲哚异喹啉化合物的药物组合物。
• Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1)
  作者：Martin Conda-Sheridan、P. V. Narasimha Reddy、Andrew Morrell、Brooklyn T. Cobb、Christophe Marchand、Keli Agama、Adel Chergui、Amélie Renaud、Andrew G. Stephen、Lakshman K. Bindu、Yves Pommier、Mark Cushman

  DOI：10.1021/jm3014458

  日期：2013.1.10

  Tyrosyl-DNA phosphodiesterase I (Tdp1) plays a key role in the repair of damaged DNA resulting from the topoisomerase I (Top1) inhibitor camptothecin and a variety of other DNA-damaging anticancer agents. This report documents the design, synthesis, and evaluation of new indenoisoquinolines that are dual inhibitors of both Tdp1 and Top1. Enzyme inhibitory data and cytotoxicity data from human cancer

  酪氨酰 DNA 磷酸二酯酶 I (Tdp1) 在修复由拓扑异构酶 I (Top1) 抑制剂喜树碱和多种其他破坏 DNA 的抗癌剂引起的受损 DNA 中发挥关键作用。本报告记录了作为 Tdp1 和 Top1 双重抑制剂的新型茚并异喹啉的设计、合成和评估。来自人类癌细胞培养物的酶抑制数据和细胞毒性数据用于建立结构-活性关系。茚并异喹啉对 Tdp1 的效力范围为 5 μM 到 111 μM，这使得活性更强的化合物成为已知的最有效的该靶标抑制剂。细胞毒性平均图中点范围为 0.02 至 2.34 μM。
• SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (Tdp1) - TOPOISOMERASE I (Top1) INHIBITORS
  申请人：Purdue Research Foundation

  公开号：US20150133445A1

  公开（公告）日：2015-05-14

  The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.

  本发明涉及合成和使用某些N-取代吲哚异喹啉化合物，其抑制酪氨酸-DNA磷酸二酯酶I（Tdp1）或拓扑异构酶I（Top1）或两者的活性，或表现出抗癌活性。还公开了新型N-取代吲哚异喹啉化合物和包含新型N-取代吲哚异喹啉化合物的制药组合物。
• Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors
  申请人：Purdue Research Foundation

  公开号：US08912213B2

  公开（公告）日：2014-12-16

  The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.

  本发明涉及合成和使用某些N-取代吲哚异喹啉化合物，其抑制酪氨酸-DNA磷酸二酯酶I（Tdp1）或拓扑异构酶I（Top1）或两者的活性，或表现出抗癌活性。还公开了新型N-取代吲哚异喹啉化合物和包含新型N-取代吲哚异喹啉化合物的制药组合物。
• Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors
  申请人：Purdue Research Foundation

  公开号：US09175002B2

  公开（公告）日：2015-11-03

  The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.

  本发明涉及合成和使用某些N-取代吲哚异喹啉化合物，其抑制酪氨酸-DNA磷酸二酯酶I（Tdp1）或拓扑异构酶I（Top1）的活性，或者表现出抗癌活性。还揭示了新型的N-取代吲哚异喹啉化合物和包含该新型N-取代吲哚异喹啉化合物的制药组合物。